Close Menu

NEW YORK – NanoString Technologies and Oregon Health & Science University on Tuesday announced a collaboration to develop GeoMx Digital Spatial Profiler-based protein assays for breast cancer.

Under the terms of the deal, pathologists at OHSU will design a new GeoMx protein assay with up to 30 targets, including existing diagnostic markers and novel biomarker candidates. They will analytically and clinically validate this and other assays for potential use as laboratory-developed tests. Financial and other details were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.